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which also completely prevented the increase in LV weight/Cardiomyocyte loss in experimental renal failure: Prevention
body weight ratio (1.83  0.14 mg/g).by ramipril.
Conclusion. LVH in renal failure is characterized by cardio-Background. The development of left ventricular hypertro-
myocyte hypertrophy, but also cardiomyocyte drop out. A rolephy (LVH) and of structural abnormalities of the heart is a
of the RAS is suggested by the beneficial effect of ramipril treat-key abnormality in renal failure that potentially contributes to
ment that is not accounted for by differences in blood pressure.the high rate of cardiac death. In renal failure, the behavior of
cardiomyocyte volume and number in the development of LVH
has so far not been investigated. A potential role of the (local)
renin-angiotensin system (RAS) in the genesis of LVH has Since the days of Richard Bright, left ventricular hy-been suspected. It was the aim of the present study in short-
pertrophy (LVH) is a well-known feature of renal failureterm experimental renal failure (1) to characterize cardiomyo-
[1]. LVH is a potent predictor of death in uremic patientscyte volume and number and (2) to study whether they are
affected by the angiotensin-converting enzyme (ACE) inhibi- [2] and survival is worst in patients with systolic dysfunc-
tor ramipril. tion [3].
Methods. Sprague-Dawley rats (N  8 to 10 per group) had The frequency and severity of LVH in renal failure
a subtotal nephrectomy (SNX) or sham operation and followed
raises suspicion that it might not be fully explained byfor 8 weeks. One SNX group received the ACE inhibitor rami-
increased afterload, the composite of blood pressure andpril (0.5 mg/kg body weight) in the drinking fluid. After perfu-
aortic compliance or by anemia [4], but that nonhemody-sion fixation, the morphology of the heart was investigated
using stereologic techniques. namic factors such as sympathetic overactivity [5], para-
Results. Systolic blood pressure was slightly, but not signifi- thyroid hormone (PTH) [6] and activity of the (local)
cantly, higher in untreated SNX, but the left ventricular (LV) renin-angiotensin system (RAS) are involved as well [7].weight and LV weight/body weight ratio (2.32  0.20 mg/g)
One particularly intriguing problem is systolic dys-were significantly higher in SNX than in sham-operated animals
function. We suspect that its prevalence is not fully ex-(1.90 0.16 mg/g). Sarcomeric length was not significantly dif-
ferent between SNX and sham-operated animals. There was an plained by the frequent occurrence of coronary heart
increase in the number of terminal deoxynucleotidyl transferase- disease in renal patients. This has led to the speculations
mediated uridine triphosphate nick end labeling (TUNEL)- about a specific entity of “cardiomyopathy” in renal fail-
positive myocytes in SNX compared to sham-operated animals
ure [8]. It is the classical view that cardiomyocytes areand a significant increase in cardiomyocyte volume (15,713 
postmitotic cells. It has recently been appreciated, how-4557 m3 vs. 10,067 2242 m3, P 0.01) as well as a decrease
ever, that cardiomyocytes are more dynamic than thoughtof cardiomyocyte numbers per unit myocardial volume (61.2
16.2 vs. 92.2  20.9  103/mm3) and per left ventricle (70.9  hitherto. Both mitosis and apoptosis have been docu-
16.5  106 vs. 94.8  18.1  106, P  0.05). Both abnormalities mented in cardiomyocytes [9, 10]. In particular, in vari-
were abrogated by treatment with ramipril (6347  972.4 m3 ous forms of heart failure, diminished numbers of cardio-and 106  18.9 103/mm3 or 118  39.5  106, respectively),
myocytes (“cardiomyocyte dropout”) has been noted [11].
These considerations prompted the present study,
which was designed to (1) clarify the role of cardiomyo-Key words: renal failure, left ventricular hypertrophy, remodeling, apo-
ptosis, ACE inhibitors. cyte volume and number in the genesis of LVH of experi-
mental renal failure and (2) study the effect of the angio-Received for publication August 19, 2002
tensin-converting enzyme (ACE) inhibitor ramipril onand in revised form November 14, 2002
Accepted for publication January 2, 2003 these parameters in order to explore a potential role of
the RAS in the genesis of LVH of renal failure. 2003 by the International Society of Nephrology
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METHODS weighted sampling and processed accordingly [13, 14].
Using the orientator technique eight pieces of the LVAnimals
muscle, including the septum, were prepared and embed-
Male Sprague-Dawley rats (200 g; Ivanovas Co., Kiss-
ded in Epon-Araldite. Semithin sections (0.8 m) were
legg, Germany) were housed in single cages at constant
stained with methylene blue and basic fuchsin and exam-
temperature (20C) and humidity (25%). The animals
ined by light microscopy with oil immersion and phase
were given a high-protein, low-salt diet containing 40% contrast at a magnification of 1000:1 [14].
protein, 0.6% NaCl, and 0.7% phosphorous (Altromin C For terminal deoxynucleotidyl transferase-mediated
1002/C 1036, Altromin Co., Lage, Germany). After 3 days uridine triphosphate nick end labeling (TUNEL) stain-
of adaptation, the animals were randomly allocated to ing and immunohistochemistry, five untreated SNX and
have a partial nephrectomy (SNX) or sham operation. five sham-operated animals were perfused with ice-cold
Blood pressure was measured at the beginning of the ex- NaCl (0.9%) under the above-described conditions. Hearts
periment and then every 2 weeks by tail plethysmography. were cut into two transversal parts; one was snap-frozen,
the other one was fixed in paraformaldehyde. Afterward,Renal ablation
frozen (8 m) and paraffin (4 m) sections were pre-
First, the right kidney was removed under ketamine/ pared and used for the TUNEL technique [15].
diazepam anesthesia (100 mg/kg or 2.5 g/kg, respec-
tively). Seven days later, the meanwhile hypertrophied TUNEL assay and immunohistology
left kidney was partially resected by removing a quantity TUNEL assay. Degradation of cardiomyocyte DNA
corresponding to two thirds of the weight of the resected was assessed in situ on transmural paraffin sections of
right kidney from the left cortex. The control animals the heart using the TUNEL technique with direct fluo-
had a sham-operation by decapsulating the kidney under rescence. The serial sections were pretreated with 0.1%
general anesthesia (see above). Special care was taken Triton X-100 [0.1% Triton X-100 in standard sodium
to avoid damage to the adrenals. (SSC) buffer] for 10 minutes. The apoptosis detection
kit was applied following the instructions of the manufac-Experimental protocol
turer (In Situ Cell Death Dectection, AP, Boehringer
The animals were randomly allocated to the following Mannheim, Germany). As a positive control, the assay
experimental groups (N  8 to 10 animals per group): kit was applied on tissue known to stain positively (glan-
(1) sham-operated controls; (2) untreated SNX animals; dula tonsillaris, supplied by the manufacturer). In addi-
and (3) SNX rats also given 0.5 mg/kg body weight/day tion, one serial transmural paraffin section was exposed
ramipril. Administration of ramipril was started 3 days to Tris buffer solution with 0.1 mg/mL DNase I bovine
postoperatively. The drug was offered in the drinking fluid serum albumin (BSA) (Serva, Heidelberg, Germany) for
at a concentration designed to deliver 0.5 mg/kg/day. 10 minutes. A transmural TUNEL assay without ter-
minal deoxynucleotidyl transferase (TdT) was used as
Perfusion fixation and tissue sampling negative control. The TUNEL staining was performed
Eight weeks after the second operation of the SNX, using fluorescein-deoxynucleotidyl uridine triphosphate
the experiment was terminated by retrograde perfusion (dUTP) and omitting the alkaline phosphatase (AP)-
fixation. The abdominal aorta was catheterized under converting step. Propidium iodide (50 g/mL) was used
ketamine/diazepam anesthesia (100 mg/kg or 2.5 g/kg, for counterstaining of nuclei for 10 minutes.
respectively) and blood samples were taken. The viscera Caspase-3 staining. For staining of the cell death-asso-
were rinsed with 10% dextran solution containing 0.5 g/L ciated protein caspase-3 in transmural paraffin sections
procaine-hydrochloride for 2 minutes. Ten seconds after of the heart, a monoclonal mouse antihuman caspase-3
starting the aortic perfusion, the vena cava was incised antibody with proofed specificity in the rat was used
to drain the blood. After dextran infusion, the vascular (Chemicon Int. Co., Hofheim, Germany, dilution 1:1500,
system was perfused with 0.2 mol/L phosphate buffer con- unconjugated primary antibody). The tissue was pre-
taining 3% glutaraldehyde at a pressure of 120 mm Hg treated with H2O2 (3% solution, 20 minutes, room temper-
for 12 minutes [12]. ature) and fetal calf serum (FCS) (Sigma, Deisenhofen,
After the perfusion, the heart and the aorta of each Germany) for 30 minutes at 37C in order to avoid unspe-
animal were removed. Weight and volume of the heart cific bindings. After incubating with the primary antibody
and left ventricle (LV) were determined and tissue sam- for 1 hour at room temperature and washing, the slices
pling and section staining was performed according to were covered with biotinylated goat antimouse immuno-
the orientator method [13, 14]. Uniformly random tissue globulin G (IgG) (polyclonal antibody, 1:20, Biogenex,
sampling was achieved by preparing a set of equidistant San Ramon, CA, USA) for 30 minutes at room tempera-
slices of the LV and the interventricular septum with a ture. Avidin D (1:2000, 30 minutes at room temperature)
was used twice and tyramid (1:100, 10 minutes at roomrandom start. Two slices of the LV were selected by area-
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temperature) preceded the staining with DAB-Kit (Vek- per view field of myocardium was determined on one
transversal cardiac section per animal at 40 magnifica-tor Co., Germany) and hematoxylin. Negative controls
tion using either fluorescent or light microscopy. Cas-were performed by omitting the primary antibody. To
pase-3 staining of cardiomyocytes was qualitatively ana-reduce run-to-run variations in the staining intensity, all
lyzed in one transversal myocardial section per animal.stainings were performed in the same run for SNX and
sham-operated sections.
StatisticsProliferating cell nuclear antigen (PCNA) assay. The
All data are expressed as mean  standard deviation.nuclear expression of the cell cycle-associated protein
After testing for normality of distribution one-way analy-proliferating cell nuclear antigen (PCNA) was assessed
sis of variance (ANOVA) was performed, followed byas a marker of cell activation and proliferation on paraf-
the “least significant difference test (LSD)” to assess thefin transmural sections of the heart [16] using a primary
differences between the groups. Differences in TUNELunconjugated antibody (anti-PCNA, monoclonal, 1:500,
results and immunohistochemical scores between SNXDako Diagnostika GmbH, Hamburg, Germany). After
and sham-operated rats were assessed using Wilcoxonpretreating with microwaves and blocking the nonspe-
U test. The zero hypothesis was rejected at P  0.05.cific binding (FCS, Sigma) for 30 minutes at 37C, the
sections were incubated with the primary antibody at
the previously determined dilution (1 hour at room tem- RESULTS
perature). Afterwards, samples were rinsed with buffer Description of the model
and incubated with a goat antimouse IgG biotin (poly-
Serum urea was significantly higher in both SNXclonal antibody, 1:20, Biogenex, room temperature for
groups compared to sham-operated controls (Table 1).30 minutes); then the incubations with super-sensitive
Hematocrit was not significantly lower in untreated SNX,label AP-conjugated streptavidin (Biogenix, 30 minutes)
but was significantly lower in ramipril-treated SNX. Cas-and Fast Red substrate (Dako, Hamburg, Germany)
ual systolic blood pressure was slightly but not signifi-were performed. After washing in deionized water, the
cantly higher in untreated SNX than in sham-operatedsections were briefly counterstained with hematoxylin
animals; it was markedly and significantly lower in theand coverslipped. The antibody had been tested for spec-
ramipril-treated SNX group. A high dose of ramipril hadificity in the rat before.
deliberately been selected to avoid confounding blood
pressure peaks, which can only be detected by telemetryMorphometric and stereologic analysis
[18]. Absolute (1.24  0.09 g in SNX vs. 1.06  0.11 g
All investigations were performed in a blinded manner in sham-operated animals) and relative LV weight was
(i.e., the observer was unaware of the study group). Ac- significantly higher in untreated SNX than in sham-oper-
cording to the orientator method, stereologic analysis ated animals indicating LVH. These parameters were
was performed on eight random samples of differently significantly lower after treatment of SNX with ramipril.
orientated sections of the LV myocardium per animal
[12–14]. Volume density (VV) of capillaries, interstitial Structural changes of the heart
tissue, and cardiomyocytes was obtained using the point- Whereas sarcomeric length was comparable in sham-
counting method according to the equation PP  VV operated animals (2.02  0.07 m), untreated SNX
(PP is point density). Reference volume was the total (2.04  0.10 m) and ramipril-treated SNX (2.06 
myocardial tissue (exclusive of noncapillary vessels, that 0.08 m) mean cardiomyocyte diameter, mean cardio-
is, arterioles and veins). Cardiomyocyte geometry was myocyte cross-sectional area (data not shown) and mean
determined using a model-based approach [17]. Cardio- cardiomyocyte volume were significantly higher (P 
myocyte diameter (md) and cardiomyocyte length (l) 0.001) in untreated SNX compared to sham-operated
were analyzed on longitudinal sections using a semiauto- controls and ramipril-treated SNX (Table 2). These find-
matic image analyzing system (Videoplan, Contron Co., ings indicate marked hypertrophy of cardiomyocytes
Eching, Germany, magnification 1:1000, oil immersion, after SNX (56%), which was prevented by ramipril
phase contrast) and corrected for contraction by stand- treatment. The main finding, however, is that the mean
ardizing on sarcomere length. Mean cardiomyocyte vol- myocyte number per LV was significantly lower in un-
ume (vmyo) was derived from vmyo  (md/2)2  l and treated SNX (	25.2%) compared to sham-operated con-
the number of cardiomyocytes per LV was calculated trols; this loss of cardiomyocytes was prevented when
according to N  VVmyo  LV volume/vmyo (with VVmyo  SNX rats were treated with ramipril.
volume density of cardiomyocytes). The number of
TUNEL assay and immunohistochemicalcardiomyocytes per volume myocardium was calculated
investigations of the heartfrom the total number devided by the volume of the LV.
In five SNX and five sham-operated control rats the The TUNEL assay and the immunohistochemical in-
vestigations were performed on transmural sections ofnumber of TUNEL and PCNA-positive cardiomyocytes
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Table 1. Description of the animal model (mean  standard deviation)
Left ventricular
weighta/body Systolic
Body weight Serum urea Hematocrit weight ratio blood pressure
g mg/dL % mg/g mm Hg
Sham operated controls
(N  10) 55731.4 544.8 44.41.5 1.900.16 10912.2
Untreated SNX
(N  8) 52538.7 11811.3b 42.62.8 2.320.20 1177.4
SNX  ramipril
(N  8) 42729.2b,c 18634.9b 38.63.5b,c 1.830.14c 9511.9b,c
ANOVA P  0.05 P  0.05 P  0.05 P  0.05 P  0.05
Abbreviations are: SNX, subtotal nephrectomy; ANOVA, analysis of variance.
a After perfusion fixation
b P  0.05 vs. sham-operated controls
c P  0.05 vs. untreated SNX
Table 2. Cardiomyocyte geometry
Mean Mean Mean number Mean number of
cardiomyocyte cardiomyocyte of myocytes per cardiomyocytes
diameter volume volume myocardium per left ventricle
lm lm3 10 3/mm 3 10 6
Sham-operated controls
(N  10) 13.11.07 10,0762242 92.220.9 94.818.1
Untreated SNX
(N  7c) 15.00.76a 15,7134557b 61.216.2a 70.916.5a
SNX  ramipril
(N  8) 11.00.67a,d 6347972.4b,e 10618.9a,d 11839.5d
ANOVA P  0.05 P  0.001 P  0.001 P  0.01
Abbreviations are: SNX, subtotal nephrectomy; ANOVA, analysis of variance. Values are given as mean  standard deviation.
a P  0.05 vs. sham-operated controls; b P  0.01 vs. sham-operated controls; c Lower number due to an outlier [33]; d P  0.05 vs. untreated SNX; e P  0.01 vs
untreated SNX
the hearts of untreated SNX and sham-operated control nonhypertensive chronic renal failure. It was found that
both cardiomyocyte hypertrophy and cardiomyocyteanimals (Fig. 1). Untreated SNX animals (Fig. 1A) showed
dropout were completely prevented by pretreatmenta higher score of TUNEL-positive cardiomyocytes nuclei
with a high dose of ramipril. It has recently been shownper area myocardium compared to sham-operated con-
that cardiomyocytes are not absolutely postmitotic andtrols (Fig. 1B). In parallel, caspase-3 staining was absent
that even in the adult organism cardiomyocytes are ablein sham-operated animals and was clearly present in
to undergo mitosis under certain conditions [20–22]. OnSNX in the cytoplasm of several cardiomyocytes per trans-
the other hand, it has been documented that cardiomyo-versal section. The number of PCNA-positive cardiomy-
cyte dropout is present in hearts of patients with severeocytes nuclei per area myocardium was significantly (P
advanced congestive heart failure [11, 23].0.005) higher in SNX (7.88  1.93) (Fig. 1C) than in
We are aware that expression of the PCNA does notsham-operated control rats (2.41  1.45) (Fig. 1D).
prove the presence of cell proliferation and we interpret
this finding as a marker of myocyte stress and activation
DISCUSSION [24]. By microscopy we were unable to see mitoses in the
The present study shows that short-term moderate hearts of the experimental animals. At any rate, if cell
experimental renal failure causes marked LVH and car- proliferation had occurred, it would have definitely been
diomyocyte hypertrophy despite only slight and statisti- outweighed by cell loss.
cally not significant increase in systolic blood pressure. It is well known that the TUNEL assay does present
This is in line with previous studies from this laboratory, methodologic problems, and the fractions of cells re-
which had shown that LVH and cardiomyocyte hypertro- ported in the literature undergoing apoptosis using this
phy in SNX animals are not fully explained by changes assay have frequently been exaggerated. Admittedly, de-
in blood pressure [7, 19]. The current study goes beyond spite the clear-cut evidence of apoptosis, the possibility
this by documenting that the number of cardiomyocytes is not excluded that the cell number also decreased as a
result of necrosis, for instance, because of circulatory prob-is significantly reduced in this model of very moderate
Amann et al: Cardiomyocyte loss in renal failure1712
Fig. 1. Myocyte apoptosis and activation in renal failure. Increased number of apoptotic myocardial cells by terminal deoxynucleotidyl transferase-
mediated uridine triphosphate nick end labeling (TUNEL) staining in untreated subtotal nephrectomy ( SNX) rats (A) compared to controls (B).
Increased number of proliferating cellular nuclear antigen (PCNA)-positive cardiomyocytes (red nuclear staining) in SNX rats (C ) compared to
sham-operated controls (D). Please note also marked hypertrophy of cardiomyocytes, as well as interstitial cell activation (arrow) in SNX (C)
compared to sham-operated control rats (D). Paraffin sections, magnification  40.
lems or invasion by interstitial tissue. A decrease in cardio- by a decrease in the number of cardiomyocytes [26] and
such cardiomyocyte dropout was ascribed to result frommyocytes per LV by 25% within 56 days could theoreti-
cally account for approximately two to three apoptotic apoptosis and/or necrosis [27].
The mechanisms leading to loss of cardiomyocytes havecells per 500 to 1000 cardiomyocytes if one makes the
somewhat unrealistic assumption that apoptotic cells re- not been well defined. It is known that the local RAS is
activated in conditions characterized by increased car-main detectable for 24 hours. This estimate shows at least
that our figures are in the proper range. diac workload [28]. The present finding that the cardio-
myocyte deficit can be prevented by administration ofTo interpret the findings in a broader context, LVH
is not only a useful adaptive phenomenon in an effort the ACE inhibitor ramipril would be consistent with the
notion that the RAS plays an important role in the con-to keep wall stress constant as had been suspected in
the past. It is known that LVH is a potent predictor of LV trol of cardiac cell numbers in renal failure [29]. To assess
the effect of ramipril, we deliberately selected a dose thatarrhythmia and cardiac death in patients with essential
hypertension [25], as well as in patients with renal failure lowered blood pressure to subnormal levels in order to
exclude the potential argument that casual blood pres-[2]. In experimental models of LVH, it had been noted
that in advanced LVH systolic dysfunction is paralleled sure measurements had underestimated the blood pres-
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12. Mall G, Greber D, Gharenhbaghi H, et al: Effects of nifedipinesure burden to blood pressure target organs [17]. There
and moxonidine on cardiac structure in spontaneously hyperten-is some information in the literature [30, 31] indicating sive rats (SHR)-stereological studies on myocytes, capillaries, ar-
that ACE inhibitors are the treatment of choice for re- teries, and cardiac interstitium. Basic Res Cardiol 3:33–44, 1991
13. Mattfeldt T, Mall G, Gharehbaghi H, et al: Estimation ofgression of cardiac hypertrophy in uremia, potentially
surface area and length with the orientator. J Microsc 159:301–improving cardiovascular survival. In a previous experi- 317, 1990
mental study in SNX rats, we found a beneficial effect of 14. To¨rnig J, Amann K, Ritz E, et al: Arteriolar wall thickening,
capillary rarefaction and interstitial fibrosis in the heart of ratsthe ACE inhibitor ramipril on cardiac interstitial tissue
with renal failure: The effects of ramipril, nifedipine and moxoni-expansion and arteriolar wall thickening [14].
dine. J Am Soc Nephrol 7:667–675, 1996
The ground breaking Canadian observational studies 15. Labat-Moleur F, Guillermet C, Lorimier P, et al: TUNEL apo-
ptotic cell detection in tissue sections: Critical evaluation and im-[3, 32] clearly documented that survival is much worse
provement critical evaluation and improvement. J Histochem Cyto-in dialyzed patients with systolic dysfunction. Although
chem 46:327–334, 1998
the mechanisms leading to systolic dysfunction have not 16. Amann K, Kronenberg G, Gehlen F, et al: Cardiac remodeling
been clarified, anecdotal observations clearly illustrate in experimental renal failure—An immunohistochemical study.
Nephrol Dial Transplant 13:1958–1966, 1998that systolic dysfunction may occur despite no overt cor-
17. Griffin KA, Picken M, Bidani AK: Radiotelemetric BP monitor-onary heart disease. ing, antihypertensives and glomeruloprotection in remnant kidney
The present observation of cardiomyocyte dropout in model. Kidney Int 46:1010–1018, 1994
18. Da¨mmrich J, Pfeifer U: Cardiac hypertrophy in rats after supraval-the absence of any evidence of ischemia might provide
vular aortic constriction. I. Size and number of cardiomyocytes,one explanation for progressive cardiac dysfunction un- endothelial and interstitial cells. Virchows Arch B Cell Pathol Incl
der these circumstances. Mol Pathol 43:265–286, 1983
19. Amann K, Mu¨nter K, Wagner J, et al: Endothelin A receptor
blockade prevents capillary/myocyte mismatch in the heart of ure-ACKNOWLEDGMENTS
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